JP2023527083A5 - - Google Patents

Info

Publication number
JP2023527083A5
JP2023527083A5 JP2022573287A JP2022573287A JP2023527083A5 JP 2023527083 A5 JP2023527083 A5 JP 2023527083A5 JP 2022573287 A JP2022573287 A JP 2022573287A JP 2022573287 A JP2022573287 A JP 2022573287A JP 2023527083 A5 JP2023527083 A5 JP 2023527083A5
Authority
JP
Japan
Prior art keywords
construct
weeks
effective dose
administering
sessions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573287A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527083A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/062728 external-priority patent/WO2021239471A1/en
Publication of JP2023527083A publication Critical patent/JP2023527083A/ja
Publication of JP2023527083A5 publication Critical patent/JP2023527083A5/ja
Pending legal-status Critical Current

Links

JP2022573287A 2020-05-29 2021-05-12 アレナウイルスベクターを使用するがんの治療方法 Pending JP2023527083A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063032362P 2020-05-29 2020-05-29
US63/032,362 2020-05-29
US202163173155P 2021-04-09 2021-04-09
US63/173,155 2021-04-09
US202163175842P 2021-04-16 2021-04-16
US63/175,842 2021-04-16
PCT/EP2021/062728 WO2021239471A1 (en) 2020-05-29 2021-05-12 Cancer treatment strategies using arenavirus vectors

Publications (2)

Publication Number Publication Date
JP2023527083A JP2023527083A (ja) 2023-06-26
JP2023527083A5 true JP2023527083A5 (enExample) 2024-06-19

Family

ID=75914543

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573287A Pending JP2023527083A (ja) 2020-05-29 2021-05-12 アレナウイルスベクターを使用するがんの治療方法

Country Status (12)

Country Link
US (1) US20230346906A1 (enExample)
EP (1) EP4157342A1 (enExample)
JP (1) JP2023527083A (enExample)
KR (1) KR20230046278A (enExample)
AU (1) AU2021282287A1 (enExample)
BR (1) BR112022024404A2 (enExample)
CA (1) CA3184791A1 (enExample)
CR (1) CR20220602A (enExample)
IL (1) IL298420A (enExample)
MX (1) MX2022014725A (enExample)
PE (1) PE20240647A1 (enExample)
WO (1) WO2021239471A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103993012B (zh) 2007-12-27 2023-01-10 苏黎士大学 复制缺陷型沙粒病毒载体
RS61993B1 (sr) 2013-12-03 2021-07-30 Hookipa Biotech Gmbh Cmv vakcine
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
EP4475879A1 (en) * 2022-02-08 2024-12-18 Hookipa Biotech GmbH Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
AU2024343172A1 (en) 2023-09-15 2026-03-05 Gilead Sciences, Inc. Arenavirus formulations, methods and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
IL262963B2 (en) 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
CN110719788A (zh) * 2017-04-07 2020-01-21 霍欧奇帕生物科技有限公司 治疗实体瘤的沙粒病毒颗粒

Similar Documents

Publication Publication Date Title
JP2022160401A5 (enExample)
JP2023524916A (ja) 腫瘍溶解性ウイルスと免疫チェックポイント阻害剤の併用による腫瘍治療
JP2016128513A5 (enExample)
FR2583429A1 (fr) Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CN108841796A (zh) 重组单纯疱疹病毒及其制备方法和应用
CN111363726A (zh) 表达干扰素的溶瘤病毒及其应用
WO2014063601A1 (zh) 诱导肿瘤特异性免疫的疫苗及其应用
CN102985094A (zh) 一种重组肿瘤疫苗及其生产方法
CN115624524A (zh) Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用
JP2023552289A5 (enExample)
WO2019201192A1 (zh) 一种用于治疗肿瘤的柯萨奇b组病毒
JP2025188115A (ja) 新規遺伝子組換えワクシニアウイルス及びその利用
JP2024523329A5 (enExample)
WO2020238427A1 (zh) 特异杀伤肿瘤细胞的溶瘤病毒系统及其应用
CN101768211A (zh) 新城疫病毒Italien株HN蛋白和F蛋白及其在基因治疗药物中的应用
CN111939262B (zh) 一种治疗肿瘤或癌症的药物组合物和其应用
CN119101706A (zh) C2l基因缺失的溶瘤痘苗病毒载体的构建方法及应用
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
JP2022513438A5 (enExample)
KR20040097249A (ko) 중공 나노입자를 형성하는 단백질에 질환 치료용 세포도입 물질을 융합시킨 약제
WO2025081515A1 (zh) 一种特异性标记异源蛋白的肿瘤新抗原疫苗体系及其应用
ZA202304877B (en) Recombinant adeno-associated viruses with enhanced liver tropism and uses thereof
JP2023526045A5 (enExample)
US20240318147A1 (en) Recombinant oncolytic virus, and construction method therefor and use thereof
JP2024511356A5 (enExample)